https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50530 Wed 28 Feb 2024 15:35:30 AEDT ]]> Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51325 Thu 31 Aug 2023 14:35:40 AEST ]]> Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5045 Sat 24 Mar 2018 07:45:38 AEDT ]]> Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26254 Sat 24 Mar 2018 07:40:18 AEDT ]]> All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25283 Sat 24 Mar 2018 07:38:13 AEDT ]]> A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18630 Mon 20 Jul 2015 16:38:11 AEST ]]> Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46198 2 days 1 to 3, and etoposide 80 mg/m² days 1 to 3 (R-IE) every 21 days for 6 cycles plus 2 doses of rituximab. Revised international prognostic index 3–4 was seen in 53% and prior rituximab exposure in 60%. The complete and overall response rates were 55% and 76%, respectively. Median progression free survival (PFS) and overall survival were 23 and 24 months, respectively. Patients relapsing within 12 months of prior treatment had a median PFS of 2.5 months compared to 23 months for those relapsing beyond 12 months. Grade 3–4 thrombocytopenia and neutropenia occurred in one and eight patients, respectively. R-IE is an effective, well tolerated regimen in RR-DLBCL patients not fit for autoSCT.]]> Mon 14 Nov 2022 11:22:52 AEDT ]]> A prospective, multicenter study of involved-field radiation therapy with autologous stem cell transplantation for patients with hodgkin lymphoma and aggressive non-hodgkin lymphoma (ALLG HDNHL04/TROG 03.03) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45459 Fri 28 Oct 2022 14:22:16 AEDT ]]> Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51501 2 smokers during childhood (OR = 1.84, 95%CI = 1.11–3.04). For cases, current smoking and the highest categories of smoking duration and lifetime cigarette exposure were associated with elevated all-cause mortality. The hazard ratio for current smoking and FL-specific mortality was 2.97 (95%CI = 0.91–9.72). We found no association between recent alcohol consumption and FL risk, all-cause or FL-specific mortality. Our study showed consistent evidence of an association between smoking and increased FL risk and possibly also FL-specific mortality. Strengthening anti-smoking policies and interventions may reduce the population burden of FL.]]> Fri 08 Sep 2023 11:56:03 AEST ]]>